JAMA Neurol Jama Neurology, 79, 3, pp. 228-243 Jama Neurology, 79, 228-243 Amyloid Biomarker Study Group 2022, ' Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum ', JAMA Neurology, vol. 79, no. 3, pp. 228-243 . https://doi.org/10.1001/jamaneurol.2021.5216 JAMA Neurology, 79(3), 228-243. American Medical Association JAMA neurology 79(3), 228-243 (2022). doi:10.1001/jamaneurol.2021.5216 Jansen, W J, Janssen, O, Tijms, B M, Vos, S J B, Ossenkoppele, R, Visser, P J & Amyloid Biomarker Study Group 2022, ' Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum ', JAMA Neurology, vol. 79, no. 3, pp. 228-243 . https://doi.org/10.1001/jamaneurol.2021.5216
Nature Communications 13(1), 6635 (2022). doi:10.1038/s41467-022-34129-4 Alzheimer’s Disease Neuroimaging Initiative 2022, ' Amyloid-associated increases in soluble tau relate to tau aggregation rates and cognitive decline in early Alzheimer's disease ', Nature Communications, vol. 13, no. 1, pp. 6635 . https://doi.org/10.1038/s41467-022-34129-4 Nature Communications, 13(1). Nature Publishing Group UK
Alzheimers & Dementia r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau Universidad Europea (UEM) PREVENT-AD Research Group, Alzheimer's Disease Neuroimaging Initiative & FACEHBI study group 2021, ' Characteristics of subjective cognitive decline associated with amyloid positivity ', Alzheimer's and Dementia . https://doi.org/10.1002/alz.12512 Alzheimer's & Dementia, 18, 1832-1845. Elsevier Science Alzheimer's and dementia 18(10), 1832-1845 (2022). doi:10.1002/alz.12512 Alzheimer's and Dementia. Elsevier Alzheimer's & dementia